Tibulizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Tibulizumab
Monoclonal antibody
Type ?
Source Humanized
Target BAFF
Clinical data
Synonyms LY 3090106
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C8934H13698N2398O2808S56
Molar mass 201.4 g/mol

Tibulizumab (LY 3090106) (INN[1]) is a humanized monoclonal antibody designed for the treatment of autoimmune diseases.

This drug was developed by Eli Lilly and Co.[2]

References[edit]